Cited by 163Cardiac electrophysiology and arrhythmiasPharmacovigilance and Adverse Drug ReactionsCystic Fibrosis Research Advances

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Macrolide Antibiotics and the Risk of Cardiac Arrhythmias

Open access

Albert, Richard K., Schuller, Joseph L.·2014·American Journal of Respiratory and Critical Care Medicine

DOI 10.1164/rccm.201402-0385ciPMC PMC4061901

Open this paper in CoChat — free account

Abstract

Randomized, controlled trials have demonstrated that chronic therapy with macrolide antibiotics reduces the morbidity of patients with cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, and nontuberculous mycobacterial infections. Lower levels of evidence indicate that chronic macrolides are also effective in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung transplant. Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, and a recent observational study prompted the FDA to strengthen the Warnings and Precautions section of azithromycin drug labels. This summary describes the electrophysiological effects of macrolides, reviews literature indicating that the large majority of subjects experiencing cardiac arrhythmias from macrolides have coexisting risk factors and that the incidence of arrhythmias in absence of coexisting risk factors is very low, examines recently published studies describing the relative risk of arrhythmias from macrolides, and concludes that this risk has been overestimated and suggests an approach to patient evaluation that should reduce the relative risk and the incidence of arrhythmias to the point that chronic macrolides can be used safely in the majority of subjects for whom they are recommended.

Integrity signals

Registry

Crossref · 10.1164/rccm.201402-0385ci

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia
Abbott, G. W., Sesti, F., Splawski, I., Buck, M. E., Lehmann, M. H., Timothy, K. W., Keating, M. T., & Goldstein, S. A. N. (1999) · Cell · doi:10.1016/s0092-8674(00)80728-x · Cited by 1,353
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Self-citation
Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs
Makkar, R. (1993) · JAMA · doi:10.1001/jama.270.21.2590 · Cited by 972
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 958
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Low Penetrance in the Long-QT Syndrome
Priori, S. G., Napolitano, C., & Schwartz, P. J. (1999) · Circulation · doi:10.1161/01.cir.99.4.529 · Cited by 800
The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
Jackman, W. M., Friday, K. J., Anderson, J. L., Aliot, E. M., Clark, M., & Lazzara, R. (1988) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(88)90014-x · Cited by 783
Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction
Gupta, S., Leatham, E. W., Carrington, D., Mendall, M. A., Kaski, J. C., & Camm, A. J. (1997) · Circulation · doi:10.1161/01.cir.96.2.404 · Cited by 705
Long QT syndromes and torsade de pointes
Viskin, S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02107-8 · Cited by 690
What Clinicians Should Know About the QT Interval
Al‐Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003) · JAMA · doi:10.1001/jama.289.16.2120 · Cited by 671
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes
Roden, D. M. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb00148.x · Cited by 662
Sex differences in the evolution of the electrocardiographic QT interval with age.
Rautaharju, P. M., Sh, Z., Wong, S., Hp, C., Berenson, G. S., Prineas, R., & Davignon, A. (1992) · PubMed · Cited by 635
The Spectrum of Symptoms and QT Intervals in Carriers of the Gene for the Long-QT Syndrome
Vincent, G. M., Timothy, K. W., Leppert, M., & Keating, M. T. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209173271204 · Cited by 621
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes
Yang, P., Kanki, H., Drolet, B., Yang, T., Wei, J., Viswanathan, P. C., Hohnloser, S. H., Shimizu, W., Schwartz, P. J., Stanton, M. S., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014448.19052.4c · Cited by 551
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
Ray, W. A., Murray, K. T., Meredith, S., Narasimhulu, S. S., Hall, K., & Stein, C. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040582 · Cited by 498
Sex Difference in Risk of Torsade de Pointes With d,l- Sotalol
Lehmann, M. H., Hardy, S. A., Archibald, D., Quart, B. D., & MacNeil, D. J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2535 · Cited by 459
Azithromycin for the Secondary Prevention of Coronary Events
Grayston, J. T., Kronmal, R. A., Jackson, L. A., Parisi, A. F., Muhlestein, J. B., Cohen, J. D., Rogers, W. J., Crouse, J. R., Borrowdale, S. L., SCHRON, E. B., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043526 · Cited by 374
Sex Hormones Prolong the QT Interval and Downregulate Potassium Channel Expression in the Rabbit Heart
Drici, M., Burklow, T. R., Haridasse, V., Glazer, R. I., & Woosley, R. L. (1996) · Circulation · doi:10.1161/01.cir.94.6.1471 · Cited by 371
KVLQT1 C-Terminal Missense Mutation Causes a Forme Fruste Long-QT Syndrome
Donger, C., Denjoy, I., Berthet, M., Neyroud, N., Cruaud, C., Bennaceur, M., Chivoret, G., Schwartz, K., Coumel, P., & Guicheney, P. (1997) · Circulation · doi:10.1161/01.cir.96.9.2778 · Cited by 357
Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection
Anderson, J. L., Muhlestein, J. B., Carlquist, J. F., Allen, A., Trehan, S., Nielson, C., Hall, S., Brady, J., Egger, M. J., Horne, B. D., et al. (1999) · Circulation · doi:10.1161/01.cir.99.12.1540 · Cited by 333
Azithromycin for the Secondary Prevention of Coronary Heart Disease Events
O’Connor, C. M., Dunne, M. W., Pfeffer, M. A., Muhlestein, J. B., Yao, L., Gupta, S., Benner, R. J., Fisher, M. R., Cook, T. D., & for the Investigators in the WIZARD Study (2003) · JAMA · doi:10.1001/jama.290.11.1459 · Cited by 324
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study
Gurfinkel, E. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1283 · Cited by 303
Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias
Napolitano, C., Schwartz, P. J., Brown, A. M., Ronchetti, E., Bianchi, L. K., Pinnavaia, A., Aquaro, G. D., & Priori, S. G. (2000) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2000.tb00033.x · Cited by 300
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1 , and KCNE2 in drug-induced long QT syndrome patients
Paulussen, A. D. C., Gilissen, R. A. H. J., Armstrong, M., Doevendans, P. A., Verhasselt, P., Smeets, H. J. M., Schulze‐Bahr, E., Haverkamp, W., Breithardt, G., Cohen, N., et al. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0522-z · Cited by 279
Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de Pointes
Antzelevitch, C. N., Sun, Z., Zhang, Z.-Q., & Yan, G. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00377-4 · Cited by 275
Evaluation of Drug-Induced QT Interval Prolongation
Malík, M., & Camm, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124050-00001 · Cited by 272
Use of Azithromycin and Death from Cardiovascular Causes
Svanström, H., Pasternak, B., & Hviid, A. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300799 · Cited by 256
U.S. Outpatient Antibiotic Prescribing, 2010
Hicks, L. A., Taylor, T. H., & Hunkler, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1212055 · Cited by 247
Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes
Milberg, P., Eckardt, L., Bruns, H.-J., Biertz, J., Ramtin, S., Reinsch, N., Fleischer, D., Kirchhof, P. F., Fabritz, L., BREITHARDT, G. E., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037911 · Cited by 231
Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes
Stone, A., Mendall, M. A., Kaski, J. C., Edger, T. M., Risley, P., Poloniecki, J. D., Camm, A. J., & Northfield, T. C. (2002) · Circulation · doi:10.1161/01.cir.0000027820.66786.cf · Cited by 199
Cardiac Actions of Erythromycin
Drici, M., Knollmann, B. C., Wang, W.-X., & Woosley, R. L. (1998) · JAMA · doi:10.1001/jama.280.20.1774 · Cited by 197
Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial
Cercek, B., Shah, P. K., Noč, M., Zahger, D., Zeymer, U., Matetzky, S., Maurer, G., & Mahrer, P. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12706-7 · Cited by 171
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
Jespersen, C. M., Als-Nielsen, B. E. T., Damgaard, M., Hansen, J. F., Hansen, S., Helø, O. H., Hildebrandt, P. R., Hilden, J., Jensen, G. B., Kastrup, J., et al. (2005) · BMJ · doi:10.1136/bmj.38666.653600.55 · Cited by 159
Impact of Sex and Gonadal Steroids on Prolongation of Ventricular Repolarization and Arrhythmias Induced byIK-Blocking Drugs
Pham, T. V., Sosunov, E. A., Gainullin, R. Z., Danilo, P., & Rosen, M. R. (2001) · Circulation · doi:10.1161/01.cir.103.17.2207 · Cited by 143
Clinical Characteristics of Patients with Ventricular Fibrillation during Antiarrhythmic Drug Therapy
Minardo, J. D., Heger, J. J., Miles, W. M., Zipes, D. P., & Prystowsky, E. N. (1988) · New England Journal of Medicine · doi:10.1056/nejm198808043190501 · Cited by 143
Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non–Q-Wave Coronary Syndrome
Sinisalo, J. P., Mattila, K. J., Valtonen, V., Anttonen, O. M., Juvonen, J., Melin, J., Vuorinen-Markkola, H., & Nieminen, M. S. (2002) · Circulation · doi:10.1161/01.cir.0000012544.07696.1f · Cited by 136
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies
Schembri, S., Williamson, P. A., Short, P. M., Singanayagam, A., Akram, A. R., Taylor, J., Singanayagam, A., Hill, A. T., & Chalmers, J. D. (2013) · BMJ · doi:10.1136/bmj.f1235 · Cited by 135
Torsades de pointes associated with drugs and toxins: Recognition and management
Stratmann, H. G., & Kennedy, H. L. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90664-8 · Cited by 133
Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs
Mosholder, A. D., Mathew, J. T., Alexander, J. J., Smith, H., & Nambiar, S. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302726 · Cited by 125
Intersubject and dose‐related variability after intravenous administration of erythromycin.
Austin, K., Mather, L. E., Philpot, C. R., & McDonald, P. (1980) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1980.tb01755.x · Cited by 112
Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome
Itoh, H., Sakaguchi, T., Ding, W., Watanabe, E., Watanabe, I., Nishio, Y., Makiyama, T., Ohno, S., Akao, M., Higashi, Y., et al. (2009) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.109.862649 · Cited by 111
Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome.
Rubart, M., Pressler, M. L., PRIDE, H. P., & Zipes, D. P. (1993) · Circulation · doi:10.1161/01.cir.88.4.1832 · Cited by 107
Antibiotic Therapy After Acute Myocardial Infarction
Zahn, R., Schneider, S., Frilling, B., Seidl, K., Tebbe, U., Weber, M. A., Gottwik, M. G., Altmann, E., Seidel, F., Rox, J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000054613.57105.06 · Cited by 106
Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism
Nattel, S., Ranger, S., Talajic, M. R., Lemery, R., & Roy, D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90305-w · Cited by 104
Erythromycin Blocks the Rapid Component of the Delayed Rectifier Potassium Current and Lengthens Repolarization of Guinea Pig Ventricular Myocytes
Daleau, P., Lessard, E., Groleau, M.-F., & Turgeon, J. (1995) · Circulation · doi:10.1161/01.cir.91.12.3010 · Cited by 100
Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors
Kezerashvili, A., Khattak, H. K., Barsky, A. A., Nazari, R., & Fisher, J. D. (2007) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-007-9124-y · Cited by 99
Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes
Owens, R. C. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.3.301.34206 · Cited by 93
Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes
Shah, R. R. (2004) · Drug Safety · doi:10.2165/00002018-200427030-00001 · Cited by 93
Amiodarone and Torsade de Pointes
Lazzara, R. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-7-549 · Cited by 93
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug–associated torsades de pointes
Lehtonen, A., Fodstad, H., Laitinen-Forsblom, P. J., Toivonen, L. K., KONTULA, K. K., & Swan, H. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.01.019 · Cited by 90
Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats
Ohtani, H., Taninaka, C., Hanada, E., Kotaki, H., Sato, H., Sawada, Y., & Iga, T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2630-2637.2000 · Cited by 78
QT Prolongation and Torsades de Pointes Associated with Clarithromycin
Lee, K. L., Jim, M., Tang, S. C. W., & Tai, Y. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00059-x · Cited by 76
QT Prolongation Associated with Azithromycin/Amiodarone Combination
Samarendra, P., KUMARI, S., Evans, S. J., Sacchi, T. J., & Navarro, V. S. (2001) · Pacing and Clinical Electrophysiology · doi:10.1046/j.1460-9592.2001.01572.x · Cited by 75
Testosterone Diminishes the Proarrhythmic Effects of Dofetilide in Normal Female Rabbits
Pham, T. V., Sosunov, E. A., Anyukhovsky, E. P., Danilo, P., & Rosen, M. R. (2002) · Circulation · doi:10.1161/01.cir.0000033596.21845.d8 · Cited by 69
Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin
McComb, J. M., Campbell, N. P. S., & Cleland, J. (1984) · The American Journal of Cardiology · doi:10.1016/s0002-9149(84)80237-4 · Cited by 69
Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).
Schoenenberger, R. A., Haefeli, W. E., Weiss, P., & Ritz, R. (1990) · BMJ · doi:10.1136/bmj.300.6736.1375 · Cited by 63
Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome
Freedman, R. A., Anderson, K. P., Green, L. S., & Mason, J. W. (1987) · The American Journal of Cardiology · doi:10.1016/s0002-9149(87)80096-6 · Cited by 62
Azithromycin-induced QT prolongation in elderly patient.
Russo, V., Puzio, G., & Siniscalchi, N. (2006) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 62
Erythromycin-Induced QT Prolongation and Polymorphic Ventricular Tachycardia (Torsades de Pointes): Case Report and Review
BRANDRISS, M. W., Richardson, W. S., & Barold, S. S. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.6.995 · Cited by 62
Comparative pharmacokinetics of macrolides
Nilsen, O. G. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/20.suppl_b.81 · Cited by 60
QT prolongation and recurrent “torsades de pointes” during erythromycin lactobionate infusion
Guélon, D., Bedock, B., Chartier, C., & Haberer, J. P. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90306-1 · Cited by 57
Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin
KIM, M. H., Berkowitz, C. E., & Trohman, R. G. (2005) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2005.50146.x · Cited by 57
A case of QT-interval prolongation precipitated by azithromycin.
Matsunaga, N., Oki, Y., & Prigollini, A. (2003) · PubMed · Cited by 56
Potentially fatal interaction between erythromycin and disopyramide
Ragosta, M., Weihl, A. C., & Rosenfeld, L. E. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90346-x · Cited by 55
Reduced repolarization reserve in ventricular myocytes from female mice
Wu, Y. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00387-x · Cited by 53
Torsade de pointes y parada cardiorrespiratoria inducida por azitromicina en una paciente con síndrome de QT largo congénito
Arellano‐Rodrigo, E., García, A., Mont, L., & Roqué, M. (2001) · Medicina Clínica · doi:10.1016/s0025-7753(01)72036-2 · Cited by 47
Torsades de Pointes Ventricular Tachycardia Induced by Clarithromycin and Disopyramide in the Presence of Hypokalemia
Hayashi, Y., Ikeda, U., Hashimoto, T., Watanabe, T., Mitsuhashi, T., & Shimada, K. (1999) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1999.tb00512.x · Cited by 46
The Effects of Erythromycin on the Electrocardiogram
Mishra, A., Friedman, H. S., & Sinha, A. K. (1999) · CHEST Journal · doi:10.1378/chest.115.4.983 · Cited by 45
QTc‐Interval Prolongation Associated with Slow Intravenous Erythromycin Lactobionate Infusions in Critically Ill Patients: A Prospective Evaluation and Review of the Literature
Tschida, S. J., Guay, D. R. P., Straka, R. J., Hoey, L. L., Johanning, R. J., & Vance‐Bryan, K. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb03650.x · Cited by 43
“Lies, Damned Lies …” and Observational Studies in Comparative Effectiveness Research
Albert, R. K. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2187oe · Cited by 42
Self-citation
Torsades de pointes induced by antibiotics
Justo, D., & Zeltser, D. (2006) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.12.003 · Cited by 41
Potentially Fatal Interaction Between Azithromycin and Disopyramide
Granowitz, E. V., TABOR, K. J., & Kirchhoffer, J. B. (2000) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2000.tb00976.x · Cited by 35
Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.
Leowattana, W., Bhuripanyo, K., Singhaviranon, L., Akaniroj, S., Mahanonda, N., Samranthin, M., & Pokum, S. (2001) · PubMed · Cited by 35
Clarithromycin Associated With Torsades de Pointes
Kamochi, H., Nii, T., Eguchi, K., Mori, T., Yamamoto, A., Shimoda, K., & Ibaraki, K. (1999) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.63.421 · Cited by 32
Torsades de Pointes Associated with Antimicrobial Therapy for Pneumonia
Lindsay, J. M., Smith, M. A., & Light, J. A. (1990) · CHEST Journal · doi:10.1378/chest.98.1.222 · Cited by 22
Treatment with Clarithromycin Prior to Coronary Artery Bypass Graft Surgery Does Not Prevent Subsequent Cardiac Events
Berg, H. F., Maraha, B., Scheffer, G. J., Ufford, M. Q.-V., Vandenbroucke‐Grauls, C. M. J. E., Peeters, M. F., & Kluytmans, J. A. J. W. (2005) · Clinical Infectious Diseases · doi:10.1086/427111 · Cited by 21
Long Q-T Syndrome Associated with Oral Erythromycin Used in Preoperative Bowel Preparation
Vogt, A. W., & Zollo, R. A. (1997) · Anesthesia & Analgesia · doi:10.1213/00000539-199711000-00010 · Cited by 21
Erythromycin induced Torsades de Pointes: case report and review of the literature.
Rezkalla, M., & Pochop, C. (1994) · PubMed · Cited by 17
[QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant].
Benoit, A., Bodiou, C., Villain, E., Bavoux, F., Checoury, A., & Badoual, J. (1991) · PubMed · Cited by 15
Effect of Erythromycin on Myocardial Repolarization in Patients With Community-Acquired Pneumonia
KDESH, A., McPherson, C. A., Yaylalı, Y. T., Yasick, D., BRADLEY, K., & Manthous, C. A. (1999) · Southern Medical Journal · doi:10.1097/00007611-199912000-00009 · Cited by 12
Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia.
de Koning, J., van der Hoeven, H., Hamer, B., & Thompson, J. A. (1994) · PubMed · Cited by 12
[Torsade de pointes induced by the combination lidocaine-erythromycin and hepatic insufficiency].
Gueugniaud, P. Y., Guérin, C., Mahul, P., Deu, C., & Robert, D. (1985) · PubMed · Cited by 12
Erythromycin pharmacokinetics in man.
Houin, G., Tillement, J. P., Lhoste, F., RAPIN, M., Soussy, C., & Duval, J. (1980) · PubMed · Cited by 11
Bioavailability of cefadroxil capsules and suspension in pediatric patients.
Ginsburg, C. M., & McCracken, G. H. (1980) · PubMed · Cited by 10
[Electrophysiological study of pro-arrhythmogenic effects of erythromycin].
Ponsonnaille, J., Citron, B., Richard, A., Trolese, J. F., Chaperon, A., Barret, B., & Gras, H. (1988) · PubMed · Cited by 9
Clarithromycin-assoziierte Synkope als Erstmanifestation eines angeborenen langen QT-Syndroms?
Wasmer, K., Hindricks, G., & Kottkamp, H. (1999) · Intensivmedizin und Notfallmedizin · doi:10.1007/s003900050273 · Cited by 8
Arrêt circulatoire peropératoire après injection intraveineuse de lactobionate d'érythromycine
Hummel, J. C., & Haberer, J. P. (1988) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(88)80022-4 · Cited by 6
Accès de torsades de pointes induits par une injection intraveineuse de lactobionate d'érythromycine
Kilani, F., & Marsepoil, T. (1988) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(88)80126-6 · Cited by 3

Research works printed but not linked: 1

Raschi, 2013, Macrolides and torsadogenic risk: emerging issues from the FDA pharmacovigilance database, J Pharmacovigilance, 1, 104

Sorted by citations

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
Gibson, P. G., Yang, I. A., Upham, J. W., Reynolds, P. N., Hodge, S. J., James, A. L., Jenkins, C. R., Peters, M. J., Marks, G. B., Baraket, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31281-3 · Cited by 685
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.03.004 · Cited by 478
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000499 · Cited by 463
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000498 · Cited by 411
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.003 · Cited by 327

See all 163

Authors: Albert, R. K., & Schuller, J. L.
Affiliations: Denver Health Medical Center (US)
Corresponding author: Albert, Richard K.
ORCID: Albert, Richard K.
Venue: American Journal of Respiratory and Critical Care Medicine
Publisher: Oxford University Press (OUP)
Published: 2014-05
Volume: 189
Issue: 10
Pages: 1173-1180
ISSN: 1073-449X (ISSN-L)
1535-4970
DOI: 10.1164/rccm.201402-0385ci
PMC: PMC4061901
OpenAlex: W2134495308
Cited by: 163
References: 89
Citations by year: 2026: 10 · 2025: 12 · 2024: 9 · 2023: 7 · 2022: 12 · 2021: 8 · 2020: 23 · 2019: 15 · 2018: 12 · 2017: 17 · 2016: 8 · 2015: 22 · 2014: 7
FWCI: 2.90
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations: American Journal of Respiratory and Critical Care Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords: macrolide antibiotics, cardiac arrhythmias, torsades de pointes, ventricular arrhythmias, azithromycin, drug safety, risk factors, cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, nontuberculous mycobacterial infection, lung transplant rejection, bronchiolitis obliterans, electrophysiological effects
MeSH terms: Anti-Bacterial Agents, Arrhythmias, Cardiac, Cystic Fibrosis, Heart Conduction System, Humans, Risk Factors, Randomized Controlled Trials as Topic, Azithromycin, Macrolides, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Macrolide Antibiotics and the Risk of Cardiac Arrhythmias

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks